UNLABELLED: AB OBJECTIVE: We aimed to investigate whether the efficacy and safety of clopidogrel plus aspirin vs aspirin alone were consistent between patients with and without intracranial arterial stenosis (ICAS), in the Clopidogrel in High-Risk Patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial. METHODS: We assessed the interaction of the treatment effects of the 2 antiplatelet therapies among patients with and without ICAS, identified by magnetic resonance angiography (MRA) in CHANCE (ClinicalTrials.gov identifier NCT00979589). RESULTS: Overall, 1,089 patients with MRA images available in CHANCE were included in this subanalysis, 608 patients (55.8%) with ICAS and 481 (44.2%) without. Patients with ICAS had higher rates of recurrent stroke (12.5% vs 5.4%; p<0.0001) at 90 days than those without. But there was no statistically significant treatment by presence of ICAS interaction on either the primary outcome of any stroke (hazard ratio for clopidogrel plus aspirin vs aspirin alone: 0.79 [0.47-1.32] vs 1.12 [0.56-2.25]; interaction p=0.522) or the safety outcome of any bleeding event (interaction p=0.277). CONCLUSIONS: The results indicated higher rate of recurrent stroke in minor stroke or high-risk TIA patients with ICAS than in those without. However, there was no significant difference in the response to the 2 antiplatelet therapies between patients with and without ICAS in the CHANCE trial. Classification of evidence: This study provides Class II evidence that for patients with acute minor stroke or TIA with and without ICAS identified byMRA, clopidogrel plus aspirin is not significantly different than aspirin alone in preventing recurrent stroke.
RCT Entities:
UNLABELLED: AB OBJECTIVE: We aimed to investigate whether the efficacy and safety of clopidogrel plus aspirin vs aspirin alone were consistent between patients with and without intracranial arterial stenosis (ICAS), in the Clopidogrel in High-Risk Patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial. METHODS: We assessed the interaction of the treatment effects of the 2 antiplatelet therapies among patients with and without ICAS, identified by magnetic resonance angiography (MRA) in CHANCE (ClinicalTrials.gov identifier NCT00979589). RESULTS: Overall, 1,089 patients with MRA images available in CHANCE were included in this subanalysis, 608 patients (55.8%) with ICAS and 481 (44.2%) without. Patients with ICAS had higher rates of recurrent stroke (12.5% vs 5.4%; p<0.0001) at 90 days than those without. But there was no statistically significant treatment by presence of ICAS interaction on either the primary outcome of any stroke (hazard ratio for clopidogrel plus aspirin vs aspirin alone: 0.79 [0.47-1.32] vs 1.12 [0.56-2.25]; interaction p=0.522) or the safety outcome of any bleeding event (interaction p=0.277). CONCLUSIONS: The results indicated higher rate of recurrent stroke in minor stroke or high-risk TIApatients with ICAS than in those without. However, there was no significant difference in the response to the 2 antiplatelet therapies between patients with and without ICAS in the CHANCE trial. Classification of evidence: This study provides Class II evidence that for patients with acute minor stroke or TIA with and without ICAS identified by MRA, clopidogrel plus aspirin is not significantly different than aspirin alone in preventing recurrent stroke.
Authors: Ka Sing Lawrence Wong; Christopher Chen; Jianhui Fu; Hui Meng Chang; Nijasri C Suwanwela; Yining N Huang; Zhao Han; Kay Sin Tan; Disya Ratanakorn; Pavithra Chollate; Yudong Zhao; Angeline Koh; Qing Hao; Hugh S Markus Journal: Lancet Neurol Date: 2010-03-22 Impact factor: 44.182
Authors: S Claiborne Johnston; J Donald Easton; Mary Farrant; William Barsan; Holly Battenhouse; Robin Conwit; Catherine Dillon; Jordan Elm; Anne Lindblad; Lewis Morgenstern; Sharon N Poisson; Yuko Palesch Journal: Int J Stroke Date: 2013-08 Impact factor: 5.266
Authors: Adnan I Qureshi; Edward Feldmann; Camilo R Gomez; S Claiborne Johnston; Scott E Kasner; Donald C Quick; Peter A Rasmussen; M Fareed K Suri; Robert A Taylor; Osama O Zaidat Journal: Ann Neurol Date: 2009-12 Impact factor: 10.422
Authors: Ka Sing Lawrence Wong; Yilong Wang; Xinyi Leng; Chen Mao; Jinling Tang; Philip M W Bath; Hugh S Markus; Philip B Gorelick; Liping Liu; Wenhua Lin; Yongjun Wang Journal: Circulation Date: 2013-09-12 Impact factor: 29.690
Authors: Pietro Caliandro; Giuseppe Reale; Andrew M Demchuk; Valeria Caso; Anita Arsovska; Chiara Iacovelli; Silvia Giovannini; Paolo Maria Rossini Journal: Neurol Sci Date: 2018-07-09 Impact factor: 3.307
Authors: Victor J Del Brutto; Seemant Chaturvedi; Hans-Christoph Diener; Jose G Romano; Ralph L Sacco Journal: J Am Coll Cardiol Date: 2019-08-13 Impact factor: 24.094